Given the implications of p21 in chemotherapeutic drug resistance [42,43], we evaluated the contribution of TFEB-mediated p21 upregulation in the capacity of cancer cells to survive upon the treatment doxorubicin. The gene discussed is CDKN1A; the disease is cancer.